Jubilant Pharmova Limited , a prominent player in the pharmaceutical sector, has announced the appointment of Arun Kumar Sharma as its interim Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), effective October 1, 2025. This strategic move comes as the company continues its search for a permanent CFO.

Board Approval and Appointment Details

The Board of Directors of Jubilant Pharmova approved Sharma's appointment on September 23, 2025, following recommendations from the Nomination, Remuneration and Compensation Committee and the Audit Committee. The decision was made during a board meeting that commenced at 10:35 a.m. and concluded at 11:20 a.m.

Transition Period and Role

Sharma's appointment is designed to ensure a smooth transition while the company progresses with its process to identify and appoint a permanent CFO. He will hold the position of CFO for an interim period until a new permanent CFO is appointed.

Arun Kumar Sharma's Extensive Experience

With over three decades of experience in the financial sector, Arun Kumar Sharma brings a wealth of knowledge to his new role at Jubilant Pharmova. His expertise spans various critical areas, including:

• Corporate finance
• Global treasury
• Investor relations
• Risk management
• Financial restructuring
• Insurance
• Capital expenditure control
• Business transformation

Previous Roles within Jubilant Bhartia Group

Sharma's appointment marks a return to the Jubilant family, as he has previously held several key positions within the Jubilant Bhartia Group:

• CFO at Jubilant Pharma Holdings Inc. USA for approximately 4 years
• CFO at Jubilant Lifesciences Limited (Chemical Business) for approximately 3 years
• CFO at Jubilant Pharmova Limited for approximately 2 years (April 2021 to May 2023)

Leadership and Value Creation

Throughout his career, Sharma has demonstrated excellence in driving sustainable growth, enhancing shareholder value, and upholding governance standards in large listed companies. His strategic and result-driven approach aligns well with Jubilant Pharmova's objectives.

Regulatory Compliance

The appointment of Arun Kumar Sharma complies with Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015. The company has duly informed the stock exchanges, BSE Limited and the National Stock Exchange of India Limited, about this significant development.

Jubilant Pharmova's decision to bring Arun Kumar Sharma on board as interim CFO reflects the company's commitment to maintaining strong financial leadership during its search for a permanent CFO. Sharma's extensive experience within the Jubilant Group and his proven track record in financial management position him well to guide the company's financial strategies in the interim period.

Jubilant Pharmova Limited has announced a significant milestone in its commitment to quality and safety standards. The company's subsidiary, Jubilant Cadista Pharmaceuticals Inc., USA, successfully completed a United States Food and Drug Administration (USFDA) Post-marketing Adverse Drug Experience (PADE) inspection on September 19, 2025, with zero observations.

Flawless Inspection Outcome

The inspection, conducted at Jubilant Cadista Pharmaceuticals Inc., concluded without any observations from the USFDA. This outcome is a testament to the company's dedication to maintaining rigorous quality control and pharmacovigilance practices in its operations.

Reaffirming Quality Commitment

Jubilant Pharmova emphasized that this successful inspection reaffirms their commitment to upholding the highest standards of quality, safety, and compliance in the pharmaceutical industry. The zero-observation result is particularly significant in the highly regulated pharmaceutical sector, where regulatory compliance is crucial for maintaining market trust and product integrity.

Corporate Structure Insights

Jubilant Cadista Pharmaceuticals Inc. is a subsidiary of Jubilant Pharma Limited, which in turn is a wholly-owned subsidiary of Jubilant Pharmova Limited. This structure highlights the company's global presence and integrated approach to pharmaceutical manufacturing and distribution.

About Jubilant Pharmova Limited

Jubilant Pharmova Limited, formerly known as Jubilant Life Sciences Limited, is a global pharmaceutical company with diverse business segments including:

• Radiopharma: Manufacturing and supply of radiopharmaceuticals with a network of 45 radiopharmacies in the US.
• Allergy Immunotherapy: Production and distribution of allergic extracts and venom products in the US, Canada, Europe, and Australia.
• Contract Development and Manufacturing Organization (CDMO): Offering services in sterile injectables, including fill and finish for both liquid and lyophilized products, as well as ophthalmic formulations.
• Contract Research and Development Manufacturing Organisation (CRDMO): Providing drug discovery services through research centers in India and France.
• Generics and Proprietary Novel Drugs: Developing innovative therapies in oncology and auto-immune disorders.

The company boasts a workforce of approximately 5,500 employees globally and is recognized as a 'Partner of Choice' by leading pharmaceutical companies worldwide.

This successful USFDA inspection further solidifies Jubilant Pharmova's position as a reliable player in the global pharmaceutical market, underlining its commitment to excellence in drug safety and quality assurance.